US Food and Drug Administration (USFDA) on 10 April 2014 approved Lupin to sell generic diabetes management drug Pioglitazone tablets in the American market. USFDA’s approval has been granted for the tablets in strengths of 15 mg, 30 mg and 45 mg. The company will shortly commence marketing the product in US.
Pioglitazone is indicated as second or third line treatment of type 2 diabetes as monotherapy and dual oral therapy. It is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
• Lupin Pharmaceuticals, Inc. is the US wholly owned subsidiary of Lupin Limited in India.
• The Company delivers the high-quality, branded and generic medications across the world.
• The company has a state-of-the-art R&D center in Pune which is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and cardiovascular drugs. It has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.